Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravenous S-005151 for intractable ulcers in dystrophic epidermolysis bullosa
jRCT2031220378Phase 2Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of redasemtide in dystrophic epidermolysis bullosa (DEB), sponsored by Shionogi & Co., Ltd. Primary endpoint: Closure of intractable ulcer. Started Oct 2022; status: active, not recruiting.
02
Drugs
redasemtide
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on jRCT2031220378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220378.